Colorado PDAB Takes Precedent-Setting Steps That Could Spur Suits

By Luke Zarzecki / February 21, 2024 at 2:44 PM
Colorado’s Prescription Drug Affordability Board voted Friday (Feb. 16) that Amgen’s Enbrel, used to treat various forms of arthritis and psoriasis, is “unaffordable,” and that Gilead Sciences’ Genvoya, a medication for HIV, was “not unaffordable.” The board is set to determine whether it will impose an upper payment limit on Enbrel on Friday (Feb. 23) -- a potentially precedent-setting move that is being closely watched by drug-price control advocates and the drug industry as other states consider setting up similar...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.